The Wolverine stack pairs BPC-157 and TB-500 — here is what preclinical research actually measured.

The Wolverine stack is a combined preparation of BPC-157 (Body Protection Compound-157) and TB-500 (a synthetic fragment of thymosin beta-4), two structurally unrelated peptides that have each accumulated independent preclinical evidence in tissue-repair models.

BPC-157 is a synthetic pentadecapeptide — fifteen amino acids in the sequence GEPPPGKPADDAGLV — derived from a protein isolated from human gastric juice. Its molecular weight is 1,419.5 Da. TB-500 corresponds to the LKKTET actin-binding motif region of thymosin beta-4 (Tβ4), a naturally occurring 43-amino acid polypeptide found at high concentrations in platelets, macrophages, and wound fluid.

The two compounds operate through complementary mechanisms at different stages of the tissue-repair cascade. BPC-157 drives angiogenesis and matrix remodeling primarily through VEGFR2 upregulation and nitric oxide signaling. TB-500 promotes endothelial and myoblast cell migration by sequestering G-actin via the LKKTET motif and suppresses inflammatory signaling through NF-kB inhibition.^[13][14]

The informal name references the accelerated tissue regeneration of a fictional character — the editorial framing captures the studied scope of activity across multiple tissue types, not a clinical claim. The combination emerged in biohacking and performance-recovery communities as a convention; it has not been tested as a co-formulation in a controlled peer-reviewed animal or human trial.

Across the BPC-157 record, the most consistent finding is accelerated tendon and ligament repair. In rats with surgically detached Achilles tendons, BPC-157 at 10 µg/kg, 10 ng/kg, and 10 pg/kg (intraperitoneal) improved functional Achilles index values, load-to-failure biomechanics, stiffness, and Young elasticity modulus compared with untreated controls — and opposed corticosteroid-induced aggravation of tendon healing.^[1] In a medial collateral ligament transection model, consistent functional, biomechanical, macroscopic, and histological improvements were observed at 90 days across intraperitoneal, topical, and oral routes at the same dose range.^[2]

Myotendinous junction disruption has also been studied. BPC-157 at 10 µg/kg and 10 ng/kg (both intraperitoneal and oral) restored myotendinous junction function, with prominent fibroblast proliferation producing reticulin and collagen fibers; untreated controls showed persistent disability.^[6] A 2025 study in rats with complete surgical quadriceps detachment found that per-oral BPC-157 recovered muscle-to-bone continuity at 3 months, with organized cortical bone formation confirmed histologically; untreated controls showed permanent healing failure.^[7]

For TB-500 (thymosin beta-4), the primary documented mechanism is G-actin sequestration — the LKKTET hexapeptide motif binds globular actin in a 1:1 complex, reducing intracellular actin concentration and promoting cell motility. In vitro, thymosin beta-4 stimulated directed migration of human umbilical vein endothelial cells four- to sixfold over media controls and upregulated matrix metalloproteinases for basement membrane remodeling.^[13]

The BPC-157 and TB-500 research record is summarized in depth on the research page, organized by compound and tissue type.

The wolverine peptide blend refers to a pre-combined lyophilized preparation containing both BPC-157 and TB-500, offered by research-supply vendors as a single reconstituted product. The distinction from the term "stack" is practical: blend implies co-formulation in a single vial; stack implies separate administration of the two compounds.

The blend convention has no peer-reviewed optimization basis. The 1:1 mass ratio most commonly described in community discussions is not derived from a published dose-optimization study — no peer-reviewed research has formally compared BPC-157:TB-500 ratios in any model.^[18] Whether co-formulation affects the activity of either compound is also unstudied.

All quantitative evidence for either component — doses, routes, timeframes, tissue targets — comes from studies examining each peptide independently. This site documents that evidence.

The BPC-157 preclinical record spans a notably broad range of injury types. Musculoskeletal models have examined tendon-to-bone avulsion,^[1] ligament transection,^[2] myotendinous junction disruption,^[6] muscle-to-bone reattachment after surgical detachment,^[7] and segmental bone defects in rabbits.^[8] Visceral models have examined gastric ulcer protection at doses of 200–800 ng/kg in rats, with ulcer inhibition ratios of 45.7–65.6% at 800 ng/kg intramuscular.^[11] Spinal cord compression injury has been examined, with BPC-157 attenuating hematoma, edema, and demyelination when administered both acutely and at day 4 of established injury.^[9]

For TB-500, injury models include skeletal muscle regeneration in dystrophin-deficient mice — 150 µg twice weekly for 6 months increased the number of regenerating skeletal muscle fibers compared with untreated controls, though no significant improvement in muscle strength or fibrosis reduction was observed^[16] — and wound healing models showing a 42% increase in reepithelialization over saline controls.^[22]

See tissue types studied for the full organized breakdown by compound and model.

BPC-157 is a synthetic pentadecapeptide derived from a gastric protein sequence; its primary studied mechanisms involve VEGFR2-driven angiogenesis and the Src-Caveolin-1-eNOS nitric oxide pathway. TB-500 is a synthetic fragment of thymosin beta-4, a 4.9 kDa polypeptide; its primary studied mechanism involves G-actin sequestration via the LKKTET motif and NF-kB anti-inflammatory signaling.

The two compounds are structurally unrelated and mechanistically distinct. They do not operate through the same pathway, target the same receptor, or share a molecular scaffold. The frequently asked question — "are they the same thing?" — has a clear answer from the literature: no. See the frequently asked questions page for a fuller breakdown.